Rausch et al. also found that all three compounds (second-generation inhibitors of the 20S proteasome carfilzomib, ixazomib or delanzomib) were highly effective for GIST cell viability and apoptosis (IC50s as low as 9 nM) with a profile similar to bortezomib, and for tumor growth in KIT-dependent GIST cell line xenografts and patient-derived xenografts (Rausch et al., 2020). This evidence concerns the gene KIT and neoplasm.